05-07-03

163/ PATENT Seq

DOCKET NO.: ISPA-3292

ATEM & TRIBE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Nielsen et al.

Confirmation No.: 9879

Application No.: 09/486,623

Group Art Unit: 1631

Filing Date: July 6, 2000

Examiner: A. Marschel

For: PEPTIDE NUCLEIC ACIDS HAVING ANTIBACTERIAL ACTIVITY

EXPRESS MAIL LABEL NO: EV 251288238 US

DATE OF DEPOSIT: May 5, 2003

EAS2758853802

Mail Stop Sequence Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 RECEIVED

MAY 0 9 2003

Sir:

TECH CENTER 1600/2900

REPLY TRANSMITTAL LETTER

	Transmitted herewith for filing in the above-identified patent application is:						
	A Preliminary Amendment.						
\boxtimes	An Amendment Responsive to the Office Action Dated February 3, 2003.						
	An Amendment Supplemental to the Paper filed .						
	Other: .						
	Applicant(s) has previously claimed small entity status under 37 CFR § 1.27.						
	Applicant(s) by its/their undersigned attorney, claims small entity status under 37 CFR § 1.27 as:						
	an Independent Inventor						
	a Small Business Concern						
	a Nonprofit Organization						

•								
DOC	KET NO.: ISPA-3292 - 2 - PATENT							
	This application is no longer entitled to small entity status. It is requested that this be noted in the files of the U.S. Patent and Trademark Office.							
	Loss of Entitlement Enclosed							
	Substitute Pages of the Specification are enclosed.							
	An Abstract is enclosed.							
	Sheets of Proposed Corrected Drawings are enclosed.							
	A Certified Copy of each of the following applications: is enclosed.							
	An Associate Power of Attorney is enclosed.							
	Information Disclosure Statement.							
	Attached Form 1449.							
	A copy of each reference as listed on the attached Form PTO-1449 is enclosed herewith.							
	Appended Material as follows:							
\boxtimes	Other Material as follows: Statement to Support Filing and Submission Accordance with 37 CFR §§ 1.821 through 1.825; Computer Readable Sequence Listing; and Paper Copy of Sequence Listing (12 pages).							

DOCKET NO.: ISPA-3292

- 3 -

PATENT

FEE CALCULATION

No Additional Fee is Due.

					SMALL ENTITY		NOT SMALL ENTITY			
	REMAINING AFTER AMENDMENT	HIGHEST PAID FOR	EXTRA	RATE	FEE	RATE	FEE			
TOTAL CLAIMS	7	32 (20 MINIMUM)		\$9 EACH	\$	\$18 EACH	\$0			
INDEP. CLAIMS	1	6 (3 MINIMUM)		\$42 EACH	\$	\$84 EACH	\$0			
FIRST PRES	ENTATION OF M	ULTIPLE DEPI	\$140	\$	\$280	\$0				
ONE MONTH EXTENSION OF TIME					\$	\$110	\$0			
TWO MONTH EXTENSION OF TIME					\$	\$410	\$0			
☐ THREE MONTH EXTENSION OF TIME					\$	\$930	\$0			
FOUR MONTH EXTENSION OF TIME					\$	\$1450	\$0			
FIVE MONTH EXTENSION OF TIME					\$	\$1970	\$0			
LESS ANY EXTENSION FEE ALREADY PAID					(\$)	minus	(\$0)			
TERMIN	IAL DISCLAIMER	<u> </u>		\$55	\$	\$110	\$0			
OTHER	FEE OR SURCHA	RGE AS FOLLO	OWS:		 					
	TOTAL FE				\$		\$0			
	A check in the amount of \$\) .00 is attached. Please charge any deficiency or credit any overpayment to Deposit Account 23-3050. Petition is hereby made under 37 CFR \(\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \									
The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to Deposit Account 23-3050. This sheet is provided in duplicate.										
	The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 23-3050. This sheet is provided in duplicate.									
	The foregoing amount due for filing this paper.									
	Any additional filing fees required, including fees for the presentation of extra claims under 37 CFR § 1.16.									

DOCKET NO.: ISPA-3292

- 4 -

PATENT

Any additional patent application processing fees under 37 CFR § 1.17 or 1.20(d).

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the U.S. Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date:

May 5, 2003

John A. Harrelson, Jr.

Registration No. 42,637

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2003 WW







IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Nielsen et al.

#19/D

Serial No.: 09/486,623

Group Art Unit: 1631

Plunkett

Filed: July 6, 2000

Examiner: A. Marschel

5/12/03

For: PEPTIDE NUCLEIC ACIDS HAVING ANTIBACTERIAL ACTIVITY

EXPRESS MAIL LABEL NO: EV 251288238 US

DATE OF DEPOSIT: May 5, 2003

Mail Stop Sequence Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RECEIVED

MAY 0 9 2003

TECH CENTER 1600/2900

REQUEST FOR RECONSIDERATION

This is in response to the Office Action mailed on February 3, 2003. Please enter the following amendments without prejudice

In the Claims:

Please amend claims 23 and 55 as shown below.

DI

23. (amended) A method of killing or inhibiting growth of bacteria comprising contacting said bacteria with a peptide nucleic acid, wherein said peptide nucleic acid comprises a sequence complementary to a target nucleic acid sequence of said bacteria, said target nucleic acid sequence being essential to the viability of said bacteria.



- 55. (amended) A method of killing or inhibiting growth of bacteria comprising:
- (a) selecting a bacteria to be killed or inhibited; and